Davey, R., Benza, R. L., Murali, S., & Raina, A. (2017). Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension. Pulm Circ.
Chicago ZitierstilDavey, Ryan, Raymond L. Benza, Srinivas Murali, und Amresh Raina. "Phosphodiesterase Type 5 Inhibitor to Riociguat Transition Is Associated With Hemodynamic and Symptomatic Improvement in Pulmonary Hypertension." Pulm Circ 2017.
MLA ZitierstilDavey, Ryan, Raymond L. Benza, Srinivas Murali, und Amresh Raina. "Phosphodiesterase Type 5 Inhibitor to Riociguat Transition Is Associated With Hemodynamic and Symptomatic Improvement in Pulmonary Hypertension." Pulm Circ 2017.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.